Bispecific antibodies could mean simpler regimens that will require fewer clinic visits, Adams said. She also mentioned the possibility of fixed-duration therapy and patients getting to the status of ...

Will Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is leading a startup ...

Optum Rx will shift to defined PMPM fees independent of list prices or utilization, eliminating spread pricing and providing client-level visibility into PBM and GPO fees. A 2028 commitment to pass ...

Madrigal licensed ARO-PNPLA3 from Arrowhead for $25 million upfront and up to $975 million in milestones, expanding a liver-directed siRNA portfolio intended to pair with resmetirom. PNPLA3 silencing ...

Microfluidic architecture with vascular and tumor chambers recreates perfusion and desmoplastic stroma, enabling longitudinal visualization of PDAC cell–stromal dynamics under near-physiologic flow.

Intratumoral ipilimumab (10× lower dose) plus IV nivolumab reduced grade 3–4 treatment-related adverse events at 6 months to 22.6% versus 57.1% with standard IV ipilimumab/nivolumab. Image-guided ...

Novo Nordisk’s oral Wegovy entered the U.S. market first, whereas Lilly’s Foundayo benefited from the FDA CNPV pilot, delivering approval roughly 50 days post-filing. Molecular modality differs ...

In this episode titled, ‘Understanding the Pathogenesis and Epidemiology of Vitiligo’, David Rosmarin led the conversation about the following questions: In this episode titled, ‘Understanding the ...

The Wall Street Journal reports that FDA Commissioner Marty Makary is being fired, signaling imminent leadership disruption at the federal drug, biologics, and device regulatory agency. Marty Makary’s ...

Coverage remains common (67%), but durability is uncertain: only 72% of covering employers expect to continue in 2027, and 10% anticipate discontinuation. Utilization management is central, including ...

Bispecific antibodies, like other treatments initially approved for later lines of therapy, are moving "upstream" in multiple myeloma treatment, Adams said. She discussed the MajesTEC-3 trial that led ...